Agilent Technologies, Inc. (A)
Agilent Technologies makes analytical instruments and lab services for chemical, pharmaceutical, and life-sciences customers.
A vs RVTY: how the two businesses compare
- Bigger business: A, with $6.9B of yearly revenue, about 2.4× RVTY's $2.9B.
- More profitable: A keeps 19 cents of each sales dollar as profit, against 8 cents at RVTY.
- More cash from each sale: A turns 22 cents of each sales dollar into operating cash flow, against 20 cents at RVTY.
From each company's latest annual SEC filing. Fiscal years can end on different dates.
Agilent Technologies (A) is the larger business by reported revenue: $6.9B in its fiscal year ended Oct 2025, about 2.4× RVTY's $2.9B (fiscal year ended Dec 2025). A's net margin was 18.8% and RVTY's 8.4%. Both file with the SEC under the same industry code, SIC 3826 (Laboratory Analytical Instruments).
Figures come from each company's own SEC filings. This page compares the businesses; it is not a price target or a verdict.
- Health Care
- Laboratory Analytical Instruments
- Same classification
- Different
- A October 31 · RVTY December 29
- Feb 24, 2026
A vs RVTY: quick comparison
| Company fact | A | RVTY |
|---|---|---|
| Company | Agilent Technologies, Inc. | Revvity, Inc. |
| Exchange | NYSE | NYSE |
| SEC industry | Laboratory Analytical Instruments | Laboratory Analytical Instruments |
| Fiscal year-end | October 31 | December 29 |
| Latest annual filing | 10-K · 2025-12-22 | 10-K · 2026-02-24 |
A vs RVTY: audited financials
- Scale: A's $6.9B of revenue is about 2.4× RVTY's $2.9B.
- Net margin: A kept 18.8% of revenue as net income versus 8.4% at RVTY.
- Cash conversion: operating cash flow equalled A 22.4% of revenue, or 1.20× net income; RVTY 20.4% of revenue, or 2.42× net income. A ratio well above 1× usually reflects non-cash charges or working-capital release; well below 1× can reflect working-capital build or non-cash gains.
- Periods: the fiscal years end about 2 months apart (2025-10-31 for A, 2025-12-28 for RVTY), so each figure reflects somewhat different demand and cost conditions.
| Metric | A | RVTY |
|---|---|---|
| Revenue | $6.9B2024-11-01 to 2025-10-31 · SEC filing | $2.9B2024-12-30 to 2025-12-28 · SEC filing |
| Net income | $1.3B2024-11-01 to 2025-10-31 · SEC filing | $241M2024-12-30 to 2025-12-28 · SEC filing |
| Operating cash flow | $1.6B2024-11-01 to 2025-10-31 · SEC filing | $583M2024-12-30 to 2025-12-28 · SEC filing |
| Diluted EPS | $4.572024-11-01 to 2025-10-31 · SEC filing | $2.072024-12-30 to 2025-12-28 · SEC filing |
| Net margin | 18.8%2024-11-01 to 2025-10-31 · SEC filing | 8.4%2024-12-30 to 2025-12-28 · SEC filing |
A: FY ending 2025-10-31 · RVTY: FY ending 2025-12-28. Figures as tagged in each issuer's SEC XBRL filing; fiscal calendars may not align.
Where A and RVTY overlap, and where they don't
Overlap
- Same SEC industry: both report under SIC 3826, Laboratory Analytical Instruments.
Differences
- Offset fiscal calendars: A's year ends October 31 and RVTY's December 29, about 2 months apart.
- Only A maps to International markets.
- Scale: A reported about 2.4× the annual revenue of RVTY.
- Profitability: net margin of 18.8% for A versus 8.4% for RVTY.
Overlap is drawn from SEC classifications and Yield Theory research themes. It is not evidence that the companies sell to the same customers or compete product for product.
Revvity, Inc. (RVTY)
Revvity provides diagnostics, life-sciences reagents, and instruments for research and clinical testing.
What moves each company
Company-specific drivers maintained by Yield Theory. Use them to decide which filing deserves deeper work; they are not predictions.
What moves A
We have not yet published a company-specific driver list for A. The primary source is Item 1 (Business) and Item 1A (Risk Factors) of its 10-K filed 2025-12-22.
What moves RVTY
We have not yet published a company-specific driver list for RVTY. The primary source is Item 1 (Business) and Item 1A (Risk Factors) of its 10-K filed 2026-02-24.
The investment question
You now know A reports about 2.4× RVTY's revenue, and A keeps more of each dollar as net income. Those are the facts. The investment question is what each share price already assumes about the laboratory analytical instruments cycle, and which evidence in the next filings would prove that assumption wrong.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchSEC filing comparison and disclosure evidence
Start with primary filings because fiscal calendars and accounting presentation can make superficially similar quarters incomparable. A's fiscal year ends October 31, while RVTY's ends December 29. Normalize the reporting periods before comparing growth, margins, capital intensity, or guidance.
The current verified House and Senate snapshot contains 12 matched transaction rows for A and 12 matched transaction rows for RVTY. These delayed, range-based disclosures can identify a filing to inspect; they do not establish motive, conviction, or a real-time trading signal.
A primary filings
RVTY primary filings
What this comparison cannot tell you
This page does not contain licensed live prices, a valuation model, earnings estimates, portfolio constraints, or a forecast of future returns. SEC classifications can be broad, company descriptions can lag strategic change, and the latest annual filing may predate a material acquisition or divestiture. Read subsequent quarterly and current reports before making a decision.
A stronger business is not automatically the better stock. Starting valuation, expectations, capital structure, cyclicality, dilution, and the probability of each thesis determine the investment outcome. Use this comparison to frame the work, then verify the numbers in the linked filings and current company disclosures.
More comparisons involving A or RVTY
A vs RVTY FAQs
Are A and RVTY direct competitors?
Agilent Technologies and Revvity share the SEC industry classification “Laboratory Analytical Instruments.” That makes the operating comparison relevant, but it does not prove that every product, customer, or revenue stream competes directly.
Is A or RVTY the bigger company by revenue?
Agilent Technologies (A) is the larger business by reported revenue: $6.9B in its fiscal year ended Oct 2025, about 2.4× RVTY's $2.9B (fiscal year ended Dec 2025). A's net margin was 18.8% and RVTY's 8.4%. Both file with the SEC under the same industry code, SIC 3826 (Laboratory Analytical Instruments). Each figure is the annual amount tagged in the company's own SEC XBRL filing; market value depends on live prices, which this page does not publish.
Which is better, A or RVTY?
There is no context-free winner. Compare the operating exposures, filing evidence, valuation, balance sheet, and risks against the specific thesis you are testing. This page deliberately does not turn a static profile into a buy or sell recommendation.
Does this A vs RVTY comparison include live prices?
No. Yield Theory does not republish unlicensed real-time market data. The financial figures on this page are the audited annual numbers Agilent Technologies, Inc. and Revvity, Inc. tagged in their SEC XBRL filings. Use a regulated broker or licensed quote provider for current prices and valuation multiples.
Where does the company information come from?
Company classifications, fiscal year-ends, and filing links come from the SEC EDGAR submissions API snapshot refreshed 2026-10-10. Business summaries and research themes are maintained by Yield Theory.
Data snapshot: SEC EDGAR submissions API, refreshed 2026-10-10. Independent educational research; not investment advice.
Which business differences matter to the investment thesis?
A vs RVTY compares reported results. The reports below show how we connect operating evidence to an investment thesis, its assumptions, catalysts, and risks. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included